• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

DVL1 sirna

Scan QR to view Datasheet
Catalog # MBS8232004
Unit / Price
Scan QR to view Datasheet
  15 nmol  /  $365 +1 FREE 8GB USB
  30 nmol  /  $515 +1 FREE 8GB USB
DVL1 sirna
Product Name

DVL1, siRNA

Full Product Name

DVL1 siRNA (Human)

Product Synonym Names
Segment polarity protein dishevelled homolog DVL-1; Dishevelled-1; DSH homolog 1
Product Gene Name
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
OMIM
601365
3D Structure
ModBase 3D Structure for O14640
Host
Synthetic
Species Reactivity
Human
Specificity
DVL1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human DVL1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of DVL1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
DVL1 sirna
siRNA to inhibit DVL1 expression using RNA interference
Applications Tested/Suitable for DVL1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for DVL1. It may not necessarily be applicable to this product.
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
72,881 Da
NCBI Official Full Name
segment polarity protein dishevelled homolog DVL-1
NCBI Official Synonym Full Names
dishevelled segment polarity protein 1
NCBI Official Symbol
NCBI Official Synonym Symbols
DVL; DRS2; DVL1L1; DVL1P1
  [Similar Products]
NCBI Protein Information
segment polarity protein dishevelled homolog DVL-1
UniProt Protein Name
Segment polarity protein dishevelled homolog DVL-1
UniProt Synonym Protein Names
DSH homolog 1
UniProt Gene Name
UniProt Synonym Gene Names
Dishevelled-1  [Similar Products]
UniProt Entry Name
DVL1_HUMAN
NCBI Summary for DVL1
DVL1, the human homolog of the Drosophila dishevelled gene (dsh) encodes a cytoplasmic phosphoprotein that regulates cell proliferation, acting as a transducer molecule for developmental processes, including segmentation and neuroblast specification. DVL1 is a candidate gene for neuroblastomatous transformation. The Schwartz-Jampel syndrome and Charcot-Marie-Tooth disease type 2A have been mapped to the same region as DVL1. The phenotypes of these diseases may be consistent with defects which might be expected from aberrant expression of a DVL gene during development. [provided by RefSeq, Jul 2008]
UniProt Comments for DVL1
DVL1: Participates in Wnt signaling by binding to the cytoplasmic C-terminus of frizzled family members and transducing the Wnt signal to down-stream effectors. Plays a role both in canonical and non-canonical Wnt signaling. Plays a role in the signal transduction pathways mediated by multiple Wnt genes. Required for LEF1 activation upon WNT1 and WNT3A signaling. DVL1 and PAK1 form a ternary complex with MUSK which is important for MUSK-dependent regulation of AChR clustering during the formation of the neuromuscular junction (NMJ). Belongs to the DSH family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Inhibitor

Chromosomal Location of Human Ortholog: 1p36

Cellular Component: microtubule; growth cone; cell soma; clathrin-coated vesicle; axon; cytoplasmic membrane-bound vesicle; cytoplasm; dendrite; synapse; cytoplasmic vesicle; cytosol; lateral plasma membrane

Molecular Function: identical protein binding; protein binding; enzyme binding; frizzled binding; Rac GTPase binding; protein kinase binding

Biological Process: neural tube development; transcription from RNA polymerase II promoter; axon guidance; Wnt receptor signaling pathway; prepulse inhibition; convergent extension involved in neural plate elongation; axon extension; Wnt receptor signaling pathway, planar cell polarity pathway; dendrite morphogenesis; heart development; neurotransmitter secretion; positive regulation of transcription, DNA-dependent; regulation of neurotransmitter levels; social behavior; Wnt receptor signaling pathway through beta-catenin; receptor clustering; cytoplasmic microtubule organization and biogenesis; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; collateral sprouting; synapse organization and biogenesis; negative regulation of protein kinase activity; negative regulation of protein binding; positive regulation of Wnt receptor signaling pathway; neuromuscular junction development

Disease: Robinow Syndrome, Autosomal Dominant; Robinow Syndrome, Autosomal Dominant 2
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000